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Abstract
The p53 codon 72 polymorphism seems to be associated with HPV-carcinogenesis, although controversial data
have been reported. A series of Brazilian women with cervix carcinomas were analyzed. Ninety-nine (67%) of 148
women were found to be homozygous (arg/arg) for the arginine polymorphism, and 49 (33%) were heterozygous
(arg/pro). This polymorphism may be an important determinant of the risk for cervix cancer, but does not seem to be
sufficient for carcinogenesis.
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Cancer of the uterine cervix is the second most fre-
quent malignancy in women in developing countries, and
responsible for substantial morbidity and mortality world-
wide. Almost all cervical carcinomas harbor HPV-DNA se-
quences, and generally the viral E6 and E7 oncoproteins are
expressed in these carcinomas (Walboomers et al., 1999).
The E6 and E7 of the oncogenic HPV types bind to p53 and
pRb proteins, respectively. The fact that the E6 protein
from the high-risk HPV can induce degradation of p53 has
led to the proposal that this p53 inactivation pathway could
play a key role in cervical carcinogenesis (Syrjänen and
Syrjänen, 1999; Brenna and Syrjänen, 2003).
Since its detection in 1987, several studies have
linked genetic polymorphism of the p53 codon 72 to
carcinogenesis and progression of cervical cancer. A per-
son can carry one of two variations of the p53 gene in codon
72: either p53 arg or p53 pro. It was suggested that
oncoprotein E6 inactivates p53arg(72) more easily than
pro(72), bearing some association with the outcome of
HPV infections. Indeed, it has been proposed that women
who are homozygous for p53arg might have a higher sus-
ceptibility to the effects of oncogenic HPV types (Storey et
al., 1998; Maciag and Villa, 1999, Makni et al., 2000).
The material of the present study consists of 148 Bra-
zilian women diagnosed and treated for HPV-positive inva-
sive cervix cancer (clinical stages I-III) in two clinics: a)
Maternity Hospital Leonor Mendes de Barros of the São
Paulo State Health Secretariat; and b) Women’s Health
Care Center of the State University of Campinas. The Eth-
ics Committees of both hospitals approved the research
plan, and written informed consent was obtained from all
patients. Diagnostic biopsies from all women were avail-
able for the study. The samples were fixed in formalin,
embedded in paraffin, and processed for 4-µm-thick HE-
stained sections. The histological diagnosis of carcinoma
was confirmed according to routine procedures.
The demonstration of a codon 72 p53 genetic poly-
morphism was performed in DNA extracted from paraf-
fin-embedded sections, using the Polymerase Chain
Reaction (PCR) technique. In brief, 4-µm sections of the tu-
mor were treated with xylene, ethanol, proteinase K, phenol
and chloroform. Pellets were resuspended in milliQ water
and stored at -20 °C. Then, 5 µL aliquots of DNA were sub-
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jected to PCR, using Master Mix (Eppendorf, Düsseldorf,
Germany) together with the following primers:
ArgF: 5’-TCC CCC TTG CCG TCC CAA -3’
ArgR: 5’-CTG GTG CAG GGG CCA CGC-3’ (144
bp)
ProF:5’-GCC AGA GGC TGC TCC CCC-3’
ProR 5’-CGT GCA AGT CAC AGA CTT-3’(177bp)
β globin F: 5’-CAA CTT CAT CCA CGT TCA
CC-3’
β globin R: 5’-GAA GAG CCA AGG ACA GGT
AC-3’
PCR was performed in separate tubes for arg, pro al-
leles, and β globin; bands were separated in 2% low-
melting point agarose stained with ethidium bromide and
analyzed using the Kodak EDAS 120 software in order to
increase sensitivity. All samples were previously analyzed
for β globin amplification, in order to check the quality and
quantity of DNA. Thermal cycling was accomplished by
using a GenAmp PCR System 9700 (Applied Biosystems).
The cycling profile, as well as the agarose gel electrophore-
sis, followed exactly the protocol used by Soulitzis et al.
(2000) (Figure 1).
Unconditional logistic regression analysis was used
to calculate odds ratios (ORs) as measures of association
between p53 polymorphism and the clinical stage, with re-
spective 95% confidence intervals (CIs). Confounding con-
trol was done by multiple logistic regression models,
resulting in adjusted ORs. The statistical analyses were
made with the SAS version 8.2 software.
The histological diagnosis of squamous cell carci-
noma (SCC) was confirmed in 144 (97%) and of
adenocarcinoma in 4 (3%) of the cases. Distribution ac-
cording to clinical stage was as follows: 40 (27%) stage I,
49 (33%) stage II, and 59 (40%) stage III. Among the 148
women, 99 (67%) were homozygous for the arginine poly-
morphism (arg/arg), 49 (33%) were heterozygous (arg/pro)
and none was homozygous for (pro/pro).
Table 1 shows the distribution of the p53 polymor-
phism according to the clinical stage. There was no signifi-
cant difference in the distribution of the polymorphism
between the clinical stages. Multiple logistic models con-
taining also the interaction terms evaluated the joint associ-
ation of polymorphisms with clinical stages, but this
analysis did not show evidence suggesting a relationship
between the variables and p53 polymorphism.
Brazil is a multiracial tropical developing country
with high incidence and mortality rates of cervix cancer,
18.32 and 4.58 per 100.000, respectively (Brasil, 2003). In
the general population, a polymorphism in p53 occurs as a
result of a proline to arginine transition at codon 72 of exon
4. There is no accurate information about the frequency of
that polymorphism in normal Brazilian women, neither in
women with cervix cancer. However, Brazilian authors
have previously evaluated 82 cases of oral squamous cell
carcinoma and 82 controls with similar population charac-
teristics, but with a different tumor biology. They found a
genotype distribution of 37.8% (31) arg/arg, 54.8% (45)
arg/pro, and 7.4% (6) pro/pro in the tumor group, and of
40.2% (33), 54.8% (45), and 4.9% (4), respectively, in the
normal population (Drummond et al., 2002).
It can be speculated that the genetic background of
the host influences the persistence of HPV infection, which
could mediate the genetic susceptibility for cervix cancer.
Storey et al. (1998) presented data suggesting that individu-
als who are homozygous arginine display a higher suscepti-
bility of p53 to degradation by the high-risk HPV E6 in
vitro. Furthermore, they found that individuals homozy-
gous for arginine were about seven times more susceptible
to HPV-associated cervix carcinoma than heterozygotes.
However, the published data on the prevalence of p53
polymorphism in cervix cancer patients are controversial.
As anticipated, the ethnic group characteristics seem to be
an important reason for discrepancies in the frequency of
this polymorphism. Thus, the frequency of the arginine al-
lele increases with latitude, while the proline allele shows
the opposite effect (Beckman et al., 1994).
In Asian women, the frequency of p53arg was found
to be relatively low: 42% (Baek et al., 2000) and 40% (Kim
et al., 2001) in Korean women; 33% (Yamashita et al.,
1999) and 44.8% (Nishikawa et al., 2000) in Japanese
women; 31% in Hong Kong women (Wong et al., 2000);
and 27% in Indian women (Bhattacharya et al., 2002). Sim-
ilar results were reported in Southern Europe. In Israel, the
frequency was 34.8% in Jewish women, 30.3% in North
African women, and 10.8% in those of other origins
(Arbel-Alon et al., 2002). The results of two series of obser-
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Table 1 - Distribution of p53 polymorphism in Brazilian women
according to the FIGO stages.
p53 polymorphism
Stages arg/arg arg/pro
n (%) n (%) crude OR
(95% CI)
adjusted* OR
(95% CI)
I 27 (27) 13 (26) Ref Ref
II 32 (33) 17 (35) 0.9 (0.3-2.2) 0.9 (0.3-2.1)
III 40 (40) 19 (39) 1.0 (0.4-2.4) 0.9 (0.3-2.1)
Total 99 (67) 49 (33)
*Adjusted for the other variables in the Table.
Figure 1 - PCR amplification of the p53 codon 72 arg allele (144 bp) and
pro allele (177 bp). Agarose and ethidium bromide, analyzed by Kodak
EDAS 120.
vations on Italian women were controversial: 34% (Tenti et
al., 2000) and 76.7% (Zehbe et al., 2001). A number of
studies on ethnically diverse groups of patients with cervix
cancer from Northern Europe have revealed a higher fre-
quency of p53arg than that observed in Asian and South
European women. Thus, the frequency of p53arg observed
in white English women was 54% (Rosenthal et al., 1998)
and 69.4% (Brady et al., 1999), in Dutch women (from the
Netherlands) 62% (van Duin et al., 2000), and in Swedish
women 63.9% (Zehbe et al., 2001).
Similar reports are available on cervical cancer pa-
tients from America, suggesting that in South and North
America the frequency of p53arg is higher than in Central
America. The results of a study carried out in Peruvian
women revealed a 50.4% frequency of p53arg (Klug et al.,
2001), and in two series of American women, the figures
were 55.9% (Madeleine et al., 2000) and 67% (Malcolm et
al., 2000), respectively. In Central America, results are
available from Mexico, showing a 45% frequency of
p53arg (Suarez-Rincon et al., 2002). Against this back-
ground, the 67% prevalence of the arg/arg polymorphism in
Brazilian women seems to be high, but it is still consistent
with the American data reported (Madeleine et al., 2000;
Malcolm et al., 2000; Klug et al., 2001; Suarez-Rincon et
al., 2002).
The controversial data found by the different studies
have been attributed to ethnic differences, but other poten-
tial confounding factors should be considered as well.
These could include the sample size, the source of DNA,
and the detection techniques used. Another important rea-
son for these discrepant results could be misclassification
of the p53 polymorphism, due to inter-laboratory variations
in protocols, affecting the ability to detect p53
polymorphisms. When the p53 polymorphism was ana-
lyzed in three different laboratories, the differences in
arg/arg genotype compared to other forms were not signifi-
cant. After exclusion of the discordant genotype, however,
the association of arg/arg p53 with cervix cancer was sig-
nificant, with an OR = 8.0 (95% CI .3-28.5) (Makni et al.,
2000).
In conclusion, such variations reflect the geographic
spread of HPVs. The p53 polymorphism may be one of the
important determinants of the risk for cervix carcinoma.
However, it does not seem to be sufficient to induce cervix
carcinogenesis or to determine the progression of the dis-
ease. The role of the genetic susceptibility to HPV infec-
tions and cervix cancer merits further investigation.
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